AR018139A1 - A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT. - Google Patents

A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT.

Info

Publication number
AR018139A1
AR018139A1 ARP990100880A ARP990100880A AR018139A1 AR 018139 A1 AR018139 A1 AR 018139A1 AR P990100880 A ARP990100880 A AR P990100880A AR P990100880 A ARP990100880 A AR P990100880A AR 018139 A1 AR018139 A1 AR 018139A1
Authority
AR
Argentina
Prior art keywords
hidroxi
halo
manufacture
same
glici
Prior art date
Application number
ARP990100880A
Other languages
Spanish (es)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR018139A1 publication Critical patent/AR018139A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12Nitrogen atoms not forming part of a nitro radical
    • C07D239/14Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de la formula (I) y a las sales aceptables para uso farmacéutico y a los isomeros de los mismos,donde X e Y son el mismo o diferente grupo halo. R es hidrogeno o alquilo C1-6. También se revela la composicion farmacéutica que lo contieney su uso en la fabricacion de medicamentos utiles para el tratamiento de afecciones mediadas por avbeta3 por inhibicion o antagonismo de lasintegrinas avbeta3.The present invention relates to compounds of the formula (I) and salts acceptable for pharmaceutical use and to the isomers thereof, where X and Y are the same or different halo group. R is hydrogen or C1-6 alkyl. It also reveals the pharmaceutical composition that contains it and its use in the manufacture of useful medicines for the treatment of conditions mediated by avbeta3 by inhibition or antagonism of lasintegrinas avbeta3.

ARP990100880A 1998-03-04 1999-03-02 A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT. AR018139A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3427098A 1998-03-04 1998-03-04

Publications (1)

Publication Number Publication Date
AR018139A1 true AR018139A1 (en) 2001-10-31

Family

ID=21875345

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100880A AR018139A1 (en) 1998-03-04 1999-03-02 A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT.

Country Status (29)

Country Link
EP (1) EP1060164A1 (en)
JP (1) JP2002505323A (en)
KR (1) KR20010041584A (en)
CN (1) CN1214011C (en)
AP (1) AP1244A (en)
AR (1) AR018139A1 (en)
AU (1) AU753230B2 (en)
BG (1) BG104740A (en)
BR (1) BR9908470A (en)
CA (1) CA2322207A1 (en)
EA (1) EA200000804A1 (en)
EE (1) EE200000506A (en)
GE (1) GEP20033118B (en)
HR (1) HRP20000574A2 (en)
HU (1) HUP0100865A3 (en)
ID (1) ID25591A (en)
IL (1) IL137653A0 (en)
IS (1) IS5582A (en)
MY (1) MY123908A (en)
NO (1) NO315703B1 (en)
NZ (1) NZ506598A (en)
OA (1) OA11530A (en)
PL (1) PL342726A1 (en)
SK (1) SK13002000A3 (en)
TR (1) TR200002542T2 (en)
UA (1) UA71906C2 (en)
WO (1) WO1999044994A1 (en)
YU (1) YU52000A (en)
ZA (1) ZA994406B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
CA2417059A1 (en) 2000-08-02 2002-02-07 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
CA2510050A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080031266A (en) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Parp modulators and treatment of cancer
EP2131861A2 (en) 2007-03-01 2009-12-16 Mallinckrodt Inc. Integrated photoactive small molecules and uses thereof
JP4792124B1 (en) * 2010-11-15 2011-10-12 エフイートレード株式会社 Method for molding protective film for vehicle and method for manufacturing protective film for vehicle
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
CN104640857B (en) 2012-07-18 2017-07-04 圣路易斯大学 As the beta amino acids derivative of integrin antagonists
KR20160147007A (en) 2014-05-30 2016-12-21 화이자 인코포레이티드 Carbonitrile derivatives as selective androgen receptor modulators
US9856201B2 (en) * 2014-06-04 2018-01-02 Monsanto Technology Llc 3,6-dichlorosalicylic acid compounds and related synthetic processes
SG11201805387RA (en) 2015-12-30 2018-07-30 Univ Saint Louis Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
MX2022014200A (en) 2020-05-14 2022-12-07 Ube Corp 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
JPWO2023085396A1 (en) 2021-11-12 2023-05-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203234T1 (en) * 1995-08-30 2001-08-15 Searle & Co META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINOBENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

Also Published As

Publication number Publication date
NO20004316L (en) 2000-11-06
WO1999044994A1 (en) 1999-09-10
IS5582A (en) 2000-08-04
MY123908A (en) 2006-06-30
BR9908470A (en) 2000-12-05
YU52000A (en) 2003-02-28
EE200000506A (en) 2002-04-15
CA2322207A1 (en) 1999-09-10
IL137653A0 (en) 2001-10-31
BG104740A (en) 2001-02-28
AU3294799A (en) 1999-09-20
HUP0100865A2 (en) 2001-08-28
HUP0100865A3 (en) 2001-11-28
ZA994406B (en) 2000-02-11
JP2002505323A (en) 2002-02-19
KR20010041584A (en) 2001-05-25
AP1244A (en) 2004-02-04
CN1214011C (en) 2005-08-10
HRP20000574A2 (en) 2001-08-31
PL342726A1 (en) 2001-07-02
CN1291978A (en) 2001-04-18
NO20004316D0 (en) 2000-08-30
OA11530A (en) 2004-05-17
ID25591A (en) 2000-10-19
TR200002542T2 (en) 2001-05-21
EP1060164A1 (en) 2000-12-20
SK13002000A3 (en) 2001-07-10
NO315703B1 (en) 2003-10-13
GEP20033118B (en) 2003-11-25
EA200000804A1 (en) 2001-04-23
AP2000001893A0 (en) 2000-09-30
NZ506598A (en) 2003-07-25
UA71906C2 (en) 2005-01-17
AU753230B2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AR018139A1 (en) A N- [3-HIDROXI-5 [(1,4,5,6-TETRAHIDRO-5-HIDROXI-2-PYRIMIDINYL) AMINO] BENZOIL] GLICI-3- (3-HALO-5-HALO-2-HYDROXYPHENYL) COMPOUND ) -BALL ALANINE, COMPOSITION PHARMACEUTICAL AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT.
ECSP034732A (en) DERIVATIVE OF PHENETHANOLAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES
PA8547701A1 (en) NUCLEOSIDS 4 SUBSTITUTED.
BR0111263A (en) 2-Aminocarbonyl-9h-purine derivatives
DE60330910D1 (en) COMPOUNDS WITH SELECTIVER INHIBITING EFFECT FOR GSK3
AR032877A1 (en) INHIBITORS FOR RENT C (1-6) -4-AMINO-AZEPAN-3-ONICOS OF PROTEASES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS, PROCEDURE FOR THE SYNTHESIS OF SUCH INHIBITORS, AND USE OF DICHES INHIBITORS THE MANUFACTURE OF MEDICINES
AR026173A1 (en) INHIBITORS OF NEURAMINIDASES.
ES2058527T3 (en) CONDENSED DERIVATIVES OF PIRIMIDINE PROCEDURE AND INTERMEDIATE COMPOUNDS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
AR009052A1 (en) THENOPYRIMIDINES, A PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL PREPARATIONS THAT CONSTITUTE THEM AND A PROCEDURE TO OBTAIN THESE PHARMACEUTICAL PREPARATIONS
BRPI0406717A (en) Compound, pharmaceutical composition comprising the same, method of treating a disease in a mammal, use of the compound and process for its production
BRPI0417458A (en) dpp-iv inhibitor compounds, pharmaceutically acceptable salts and prodrugs thereof, their preparation processes, pharmaceutical composition comprising them and use of said compounds in the manufacture of medicaments
AR035792A1 (en) COMPOUNDS OF N- (4-QUINAZOLINIL) -N- (1H-INDAZOL-5-IL) AMINA, INHIBITOR OF RHO-KINASE, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND METHOD TO PREPARE IT
AR029403A1 (en) N-SUBSTITUTED DERIVATIVES OF CARBAMOILOXIALQUIL-AZOLIO, A PROCESS FOR ITS MANUFACTURE, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT
BR9908545A (en) Piperidine derivative, process for preparing it, compound, process for preparing it, and pharmaceutical composition
BR0113234A (en) Polymorphs of an epothilone analog
UY26872A1 (en) DERIVATIVES OF THE 4- PIRIDINE PHENYL
AR008377A1 (en) A COMPOUND DERIVED FROM 3-AROYLBENCIL-PIRIDAZINONE, A PARTICULAR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES CONTAINING SUCH A COMPOUND
ECSP034744A (en) N-REPLACED N-REPLACED NMDA / NR2B ANTAGONISTS
ATE406893T1 (en) PHARMACEUTICAL COMPOSITION (KIT) CONTAINING DIHYDROPYRIDINONE COMPOUNDS AND A COMPOUND HAVING IMMUNOMODULATORY (OR ANTI-INFLAMMATORY) ACTION AND USE THEREOF
ES2158778B1 (en) PAROXETINE SALT COMPOUNDS, THEIR PREPARATION AND USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR003440A1 (en) NEW AMINO ACID DERIVATIVES, PHARMACEUTICAL FORMULATION CONTAINING THEM, USE OF SUCH DERIVATIVES TO PREPARE MEDICINES AND PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES.
BR0214243A (en) Sulfonamide derivative Process for the preparation of a sulfonamide derivative and its physiologically acceptable salts, pharmaceutical composition and use of a sulfonamide derivative
ATE383339T1 (en) AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS
UY27700A1 (en) OXO COMPOUNDS - AZABYCLES.
AR004961A1 (en) (R) - (-) - 2- {N- [4- (1,1-DIOXIDO-3- OXO-2,3-DIHIDRO-BENZISOTIAZOLE-2-IL) -BUTYL] -AMINOMETIL CRYSTALLINE V MODIFICATION ) CHROMAN, A PROCEDURE FOR ITS PREPARATION, MEDICINES CONTAINING IT, THE USE OF SUCH CHLORHYDRATE FOR THE PREPARATION OF MEDICINES, A COMPOSITION FOR

Legal Events

Date Code Title Description
FB Suspension of granting procedure